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Introduction authority” is the Medical Devices Agency, which del-
egates operational responsibilities to independent or-
The article on the U.K. Registry for the Endovascular ganisations (notified bodies) such as The British
Standards Institute.5Treatment of Aneurysms (RETA) in this month’s edi-
tion of the Journal1 raises questions about the value The European directive covers only safety, not
efficacy, and concern remains about the uniformityof such registries. The wider issues concerning the
evaluation of new technology also require discussion. of safety standards imposed by individual countries.6
In the U.K. the Government’s Advisory CommitteeThroughout Europe, regulations exist to prevent the
use of new drugs until their safety and effectiveness on Science and Technology recommended the es-
tablishment of “a committee on safety and efficacyhave been proved. However, until recently there were
no regulations regarding the introduction of new inter- of procedures to review and register novel surgical
procedures” with statutory powers similar to the Com-ventional procedures and the technology associated
with them. The uncontrolled introduction of new tech- mittee for Safety of Medicines.7 The Department of
Health rejected this proposal in favour of a voluntarynology without proper evaluation has caused serious
problems. The complications associated with the hasty system of registration, established under the auspices
of the Medical Royal Colleges.8 The Safety and Efficacyadoption of laparoscopic cholecystectomy led to much
adverse publicity.2 Unfortunately, vascular surgeons Register of New Interventional Procedures (SERNIP)
classifies new procedures as follows:and radiologists do not appear to have learned from
the mistakes made by their general surgical colleagues.
(a) Safety and efficacy established; procedure may beEndovascular aortic aneurysm repair (EVAR) holds
used.great promise for clinicians and patients alike. How-
(b) Sufficiently close to an established procedure toever, the desire for publicity and financial reward has
give no reasonable grounds for questioning safetyled to its uncritical adoption by many centres.3 The
and efficacy, procedure may be used.disintegration of some first-generation aortic stent
(c) Safety and efficacy not yet established: proceduregrafts has recently caused great concern.4
requires a fully controlled evaluation and may beOn 1st January, 1995 a new European directive
used only as part of systematic research comprisingcovering implantable medical devices became effect-
either an observational study (ci) or a randomisedive. This required all medical devices to bear a CE
controlled trial (cii).mark from 14th June, 1998. The CE mark indicates
(d) Safety and/or efficacy shown to be unsatisfactory:that the device meets the essential safety requirements.
procedures should not be used.Many countries in the European Union have re-
organised their ministries of health to implement these
SERNIP liaises with the Standing Group on Healthdirectives. In the U.K. the responsible “competent
Technology Assessment (HTA) regarding funding of
research for unproven procedures. SERNIP has clas-
sified endovascular AAA repair as cii and the HTA∗Address for correspondence: J. D. Beard, Sheffield Vascular
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EVAR vs. conventional AAA repair in the U.K. Other against conventional treatment may jeopardise the
results if carried out too early but delaying the startcountries including France and Netherlands have sim-
ilar organisations and may fund similar trials.9 Al- of randomisation may risk loss of clinical equipoise,
i.e. the surgeon and/or patient will no longer acceptthough SERNIP is voluntary, many health authorities
in the U.K. will not fund procedures in Category (d), the conventional treatment. Russell and others have
argued for more pragmatic trials.16 The tracker trialand only those in Category (c) if part of a study or
trial. The newly created National Institute for Clinical design advocated by Lilford et al.17 incorporates some
degree of flexibility that adapts the trial protocol toExcellence does have the power to veto the use of new
drugs or technology on a cost-effectiveness basis. This changes in new technology whilst retaining the ad-
vantages of a RCT. Tracker trials possess the followinghas raised accusations of rationing on cost grounds
alone.10 features:
The Joint Working Party of the Vascular Surgical • Early randomisation of new treatments by all centres
Society of Great Britain and Ireland and the British performing them.
Society of Interventional Radiologists agreed prin- • A flexible protocol without a prefixed sample size
ciples regarding the introduction of EVAR in 1996.11 or trial duration.
These principles stated that EVAR should be assessed • Monitoring of treatments and centres to provide an
initially in centres that satisfied certain criteria in- early warning system.
cluding:
The U.K. EVAR Trial incorporates some elements of• Clear evidence of association between Vascular Sur-
tracker trial design. The Trial Management Committeegeons and Vascular Radiologists.
will evaluate new devices and centres for inclusion• Specific training in EVAR before embarking upon
into the trial and the Trial Monitoring Committee willindependent practice.
monitor devices and centres for adverse events.• Adequate workload in terms of conventional repair
With the advent of tracker trial and other pragmaticand acceptable mortality.
designs there seems little excuse for surgeons or com-• A detailed audit of results and submission of data
mercial companies to avoid early formal assessmentto a central registry (RETA).
of new technology and interventions. However, such
The purpose of the Registry was to facilitate efficient, assessment will usually require a large multicentre
timely analysis of outcomes and thereby permit early, trial and funding at a national or European level may
wider dissemination of EVAR, subject to the results take years to obtain. The proposal that commercial
from the pilot centres being satisfactory. The voluntary companies should contribute financially to such trials
nature of the registry raises questions about the com- seems controversial and beyond the scope of this
pleteness and accuracy of the returned data.12 How- article. In the meantime, registries such as RETA will
ever, checks with commercial companies suggest a continue to have a place as a means of gathering early
data return rate of about 90% of the devices implanted data, free of individual or commercial bias. National
in the U.K. Conformity with the Registry was further Vascular Societies and the European Vascular Society
improved by the decision of the EVAR Trial Man- should promote and support such registries, which
agement Committee to use RETA as the “front door” can facilitate the funding of subsequent randomised
to entry into the randomised trial and data from the trials.
Registry contributed to the successful funding of the
EVAR Trial. Therefore, the Registry appears to have
fulfilled its original aims and we must now wait
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